
AN2 Therapeutics
Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.
About
AN2 Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, melioidosis, and NTM lung disease caused by M. abscessus, along with programs focused on targets in oncology and infectious diseases.
Listed competitors
Biotechnology company focused on developing cancer immunotherapies.
Global biopharmaceutical company focused on oncology and neuroscience treatments.
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Show 6 more similar companies
Also in this space
Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.
Shares Biotechnology, Drug Discovery
A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
Shares Biotechnology, Life Sciences
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
Shares Biotechnology, Drug Discovery
Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
Shares Biotechnology, Pharmaceuticals
Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
Shares Biotechnology, Pharmaceuticals
Signals agent
Reach companies that have budget right now
Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.
- Just raised a roundFresh budget, the week it lands
- Hiring sales and marketingGo-to-market roles mean money to spend
- Hiring fastA jump in open roles across the company
- In the newsLaunches and announcements worth a message
- The decision makerWho to contact, with a message you can edit
Is your startup an alternative to AN2 Therapeutics?
People comparing tools land here. Get listed beside these.
Copy AN2 Therapeutics's SEO strategy
How often they publish, which searches their posts chase and their newest posts. Then outrank them.
All funding rounds
Key facts
- Website
- an2therapeutics.com
- Headquarters
- Menlo Park, United States
- Founded
- 2018
- Founders
- George H. Talbot, Joseph S. Zakrzewski, Eric Easom, Michael R.K. Alley
- Total funding
- $132M (Private Placement)
- Business model
- B2B
Funding rounds
- $40M9 Mar 2026
- $80M7 Jan 2022Series BLargest round
- $12M21 Nov 2019
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 9 Mar 2026 | Private Placement | $40M | |
| 7 Jan 2022 | Series B | $80M | |
| 21 Nov 2019 | Series A | $12M |
Tech stack
Detected on an2therapeutics.com, last scanned 13 Nov 2026. Run your own scan
- Frontend
- jQuery, Bootstrap
- Analytics
- Google Analytics 4
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Cookie consent
- Cookiebot
Benchmarking
See how your site ranks against 16,849 startups
AN2 Therapeutics sits in the 39th percentile for Domain Rating. Check where yours lands, free.
AN2 Therapeutics has a Domain Rating of 31, the 39th percentile of 16,849 startups we track.
Measured, not editorial
Ahrefs DR
Below median
Check yoursAgent Readiness
Top 25%
Scan yoursSite Speed
Above median
PageSpeedData Trust
Top 25%
Security
Click to scan
Agent Readiness
Can AI agents use your site?
AN2 Therapeutics scores 62. Check yours free in a few seconds, or let Max Agent rerun it daily.
Run it daily with Max AgentGet notified when AN2 Therapeutics changes
Used AN2 Therapeutics? Write a review and get $5 in credits
Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:
- Email finder
- Market Map Maker
- Agent Readiness scans
- Deep intel
- Tech stack scans
Frequently asked
Is AN2 Therapeutics growing?
Yes, fast. Our data shows it raised $40M in a Private Placement in March 2026.
Who owns AN2 Therapeutics?
AN2 Therapeutics is privately held, owned by its founders and investors. Investors on record include Citadel. Exact stakes are not public.
Are there companies like AN2 Therapeutics?
Yes. We list 9 companies like AN2 Therapeutics, including Juno Therapeutics, Jazz Pharmaceuticals and Moderna.
What does AN2 Therapeutics do?
They are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.
Is AN2 Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for AN2 Therapeutics is 80 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has AN2 Therapeutics raised?
AN2 Therapeutics has raised a total of $132M in funding. The most recent round on record is Private Placement.
SEC filings, insider activity, nonprofit links and pay benchmarks for AN2 Therapeutics:
Company details: from public sources. Funding: 3 rounds on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
Categories
Max Agent
Let Max Agent watch AN2 Therapeutics and its market for you
New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.
Free week
Starter listings, once
AI answers checked
Daily for 7 days
ChatGPT
Perplexity
Max Agent
$79 a month, or $9.99 with our badge on your site
AI answers checked
Every week
ChatGPT
Claude
Perplexity
Gemini


